About US
Contact us
-
Takeda's Velcade successor gets quick FDA approvalJust a couple of months after accepting the application, theFDAhas approvedTakeda Pharmaceutical's Ninlaro, a treatment for multiple myeloma that the Japanese company hopes can get established before2015/11/23
-
Novartis snags new approvals for Cosentyx in EuropeNovartis ($NVS) has been jockeying for additional uses for its next-gen psoriasis med,Cosentyx, hoping that a trifecta of indications will help generate blockbuster sales and distinguish the drug from2015/11/23
-
Adapt's new bargain-priced OD antidote enters contentious marketThe rising number of opioid-related deaths in the U.S. has translated into big opportunity for pharmas selling the antidote med naloxone, with drugmakers such as Amphastar Pharmaceuticals ($AMPH) gett2015/11/20
-
Pfizer prepared to risk a 3% breakup fee for chance at Allergan, sources tell ReutersBreaking up can be hard to do. It can also be expensive, which would be the case for Pfizer if the roughly $150 billion deal it is reportedly negotiating with Allergan were to go south. But the potent2015/11/20
-
Big three PBMs cut loose more specialty pharmacies as scrutiny growsPharmacy benefit managershave broadened their crackdown on specialty pharmacies, with at least 8 cut off from reimbursement in recent days. The PBMs are targeting pharmacies with close ties to particu2015/11/17
-
History suggests a Pfizer-Allergan hookup would mean sizable cuts in manufacturingToday Pfizer ($PFE) has about 65 plants since picking upHospirain September. A hookup with Allergan ($AGN), which the two have acknowledged they are exploring, would add another 40. That inevitably le2015/11/17
-
Merck may appeal to Supreme Court after again losing fight to protect Cubicin patentsMerck & Co. ($MRK) is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics of the antibioticCubic2015/11/16
-
Mylan fails in hostile quest to buy PerrigoPharma's longest-running takeover battle of the year has come to an end--and not in pursuer Mylan's ($MYL) favor. The company has failed to garner the support necessary for a takeover of Perrigo ($PR2015/11/16
-
AstraZeneca hikes full-year forecast as Nexium holds its own, Brilinta deliversAstraZeneca ($AZN) has so far weathered theNexiumpatent cliff well enough to actually raise its full-year sales forecast for 2015. ItsBrilintagrowth strategy appears to be paying off. But the U.K.-bas2015/11/6
-
U.K. cancer fund strikes discount deal with Roche to keep Kadcyla coveredLast month, the U.K.'s special Cancer Drugs Fund gave the boot to a slate of therapies, including Roche's ($RHHBY) treatmentKadcyla--a decision the Swiss drugmaker's CEO called "stupid" and "completel2015/11/6